The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma
- Resource Type
- Journal
- Authors
- Soumerai, Jacob D.; Zelenetz, Andrew D.; Moskowitz, Craig H.; Palomba, M. Lia; Hamlin, Paul A., Jr.; Noy, Ariela; Straus, David J.; Moskowitz, Alison J.; Younes, Anas; Matasar, Matthew J.; Horwitz, Steven M.; Portlock, Carol S.; Konner, Jason A.; Gounder, Mrinal M.; Hyman, David M.; Voss, Martin H.; Fury, Matthew G.; Gajria, Devika; Carvajal, Richard D.; Ho, Alan L.; Beumer, Jan H.; Kiesel, Brian; Zhang, Zhigang; Chen, Alice; Little, Richard F.; Jarjies, Christine; Dang, Thu O.; France, Fallon; Mishra, Nishant; Gerecitano, John F.
- Source
- CLINICAL CANCER RESEARCH; AUG 1 2017, 23 15, p4119-p4126, 8p.
- Subject
- Language
- English
- ISSN
- 15573265